Publications
Learn more about the work that we do in the Schnitzer laboratory through our recent publications.
- Langford DJ, Mark RP, France FO, Nishtar M, Park M, Sharma S, Shklyar IC, Schnitzer TJ, Conaghan PG, Amtmann D et al. Use of patient-reported global assessment measures in clinical trials of chronic pain treatments: ACTTION systematic review and considerations. Pain 2024 Nov 01;165(11):2445-2454. doi:10.1097/j.pain.0000000000003270
- Crack LE, Simonian N, Schnitzer TJ, Edwards WB Monthly treatment with romosozumab for 1 year increases bone mineral at the hip, but not the knee, in women with chronic spinal cord injury. JBMR Plus 2024 Jul;8(7):ziae077. pii:ziae077
- Schnitzer TJ, Conaghan PG, Berenbaum F, Abraham L, Cappelleri JC, Bushmakin AG, Viktrup L, Yang R, Brown MT Effect size varies based on calculation method and may affect interpretation of treatment effect: an illustration using randomised clinical trials in osteoarthritis. Adv Rheumatol 2024 Apr 22;64(1):31. doi:10.1186/s42358-024-00358-y
- Espinosa-Salas S, Bagherzadeh L, Wafford QE, Witte G, Schnitzer TJ Does sex affect the efficacy of systemic pharmacological treatments of pain in knee osteoarthritis? A systematic review. Osteoarthr Cartil Open 2024 Mar;6(1):100438. pii:100438
- Baliki MN, Vigotsky AD, Rached G, Jabakhanji R, Huang L, Branco P, Cong O, Griffith J, Wasan AD, Schnitzer TJ et al. Neuropsychology of chronic back pain managed with long-term opioid use. medRxiv 2024 Feb 08;. pii:2024.02.07.24302408
- Carrino JA, McAlindon TE, Schnitzer TJ, Guermazi A, Hochberg MC, Conaghan PG, Brown MT, Burr A, Fountaine RJ, Pixton GC et al. Characterization of adverse joint outcomes in patients with osteoarthritis treated with subcutaneous tanezumab. Osteoarthritis Cartilage 2023 Dec;31(12):1612-1626. doi:10.1016/j.joca.2023.08.010
- Barroso J, Branco P, Pinto-Ramos J, Vigotsky AD, Reis AM, Schnitzer TJ, Galhardo V, Apkarian AV Subcortical brain anatomy as a potential biomarker of persistent pain after total knee replacement in osteoarthritis. Pain 2023 Oct 01;164(10):2306-2315. doi:10.1097/j.pain.0000000000002932
- Crack LE, Haider IT, Simonian N, Barroso J, Gabel L, Schnitzer TJ, Edwards WB Zoledronic acid after spinal cord injury mitigates losses in proximal femoral strength independent of ambulation ability. Osteoporos Int 2023 Sep;34(9):1637-1645. doi:10.1007/s00198-023-06811-w
- Mazur CM, Edwards WB, Haider IT, Fang Y, Morse LR, Schnitzer TJ, Simonian N, Troy KL Bone Mineral Loss at the Distal Femur and Proximal Tibia Following Spinal Cord Injury in Men and Women. J Clin Densitom 2023;26(3):101380. doi:10.1016/j.jocd.2023.101380
- Schnitzer TJ, Robinson RL, Viktrup L, Cappelleri JC, Bushmakin AG, Tive L, Berry M, Walker C, Jackson J Opioids for Osteoarthritis: Cross-Sectional Survey of Patient Perspectives and Satisfaction. J Clin Med 2023 Apr 06;12(7). pii:2733
- Schnitzer TJ, Robinson RL, Viktrup L, Cappelleri JC, Bushmakin AG, Tive L, Berry M, Walker C, Jackson J Opioid Prescribing for Osteoarthritis: Cross-Sectional Survey among Primary Care Physicians, Rheumatologists, and Orthopaedic Surgeons. J Clin Med 2023 Jan 11;12(2). pii:589
- Atkinson J, Edwards RA, Bonfanti G, Barroso J, Schnitzer TJ A Two-Step, Trajectory-Focused, Analytics Approach to Attempt Prediction of Analgesic Response in Patients with Moderate-to-Severe Osteoarthritis. Adv Ther 2023 Jan;40(1):252-264. doi:10.1007/s12325-022-02336-6
- Markman JD, Schnitzer TJ, Perrot S, Beydoun SR, Ohtori S, Viktrup L, Yang R, Bramson C, West CR, Verburg KM Clinical Meaningfulness of Response to Tanezumab in Patients with Chronic Low Back Pain: Analysis From a 56-Week, Randomized, Placebo- and Tramadol-Controlled, Phase 3 Trial. Pain Ther 2022 Dec;11(4):1267-1285. doi:10.1007/s40122-022-00424-7
- Schnitzer TJ, Bonfanti G, Atkinson J, Donevan S, Viktrup L, Barroso J, Whalen E, Edwards RA Characterizing 16-Week Responder Profiles Using Group-Based Trajectory Modeling in Over 4300 Clinical Trial Participants Receiving Pharmaceutical Treatment for Moderate to Severe Osteoarthritis. Adv Ther 2022 Oct;39(10):4742-4756. doi:10.1007/s12325-022-02290-3
- Hunter DJ, Schnitzer TJ, Hall J, Semel D, Davignon I, Cappelleri JC, Bushmakin AG, Abraham L Time to first and sustained improvement in WOMAC domains among patients with osteoarthritis receiving tanezumab. Osteoarthr Cartil Open 2022 Sep;4(3):100294. pii:100294
- Conaghan PG, Dworkin RH, Schnitzer TJ, Berenbaum F, Bushmakin AG, Cappelleri JC, Viktrup L, Abraham L WOMAC Meaningful Within-patient Change: Results From 3 Studies of Tanezumab in Patients With Moderate-to-severe Osteoarthritis of the Hip or Knee. J Rheumatol 2022 Jun;49(6):615-621. doi:10.3899/jrheum.210543
- Berenbaum F, Schnitzer TJ, Kivitz AJ, Viktrup L, Hickman A, Pixton G, Brown MT, Davignon I, West CR General Safety and Tolerability of Subcutaneous Tanezumab for Osteoarthritis: A Pooled Analysis of Three Randomized, Placebo-Controlled Trials. Arthritis Care Res (Hoboken) 2022 Jun;74(6):918-928. doi:10.1002/acr.24637
- Schnitzer TJ, Robinson RL, Tive L, Cappelleri JC, Bushmakin AG, Jackson J, Berry M, Barlow S, Walker C, Viktrup L Factors associated with physician-reported treatment status of patients with osteoarthritis pain. BMC Musculoskelet Disord 2022 May 26;23(1):498. pii:498
- Vachon-Presseau E, Abdullah TB, Berger SE, Huang L, Griffith JW, Schnitzer TJ, Apkarian AV Validating a biosignature-predicting placebo pill response in chronic pain in the settings of a randomized controlled trial. Pain 2022 May 01;163(5):910-922. doi:10.1097/j.pain.0000000000002450
- Robinson RL, Schnitzer TJ, Barlow S, Berry M, Bushmakin AG, Cappelleri JC, Tive L, Jackson J, Jackson J, Viktrup L Satisfaction with Medications Prescribed for Osteoarthritis: A Cross-Sectional Survey of Patients and Their Physicians in the United States. Pain Ther 2022 Mar;11(1):191-208. doi:10.1007/s40122-021-00350-0
- Edwards WB, Haider IT, Simonian N, Barroso J, Schnitzer TJ Reply to Letter to the Editor Regarding "Durability and Delayed Treatment Effects of Zoledronic Acid on Bone Loss After Spinal Cord Injury: A Randomized, Controlled Trial". J Bone Miner Res 2022 Jan;37(1):169-170. doi:10.1002/jbmr.4456
- Schnitzer TJ, Berenbaum F, Conaghan PG, Dworkin RH, Gatti D, Yang R, Viktrup L, Davignon I, West CR, Verburg KM Single and Composite Endpoints of Within-Patient Improvement in Symptoms: Pooled Tanezumab Data in Patients with Osteoarthritis. Rheumatol Ther 2021 Dec;8(4):1759-1774. doi:10.1007/s40744-021-00372-2
- Reckziegel D, Tétreault P, Ghantous M, Wakaizumi K, Petre B, Huang L, Jabakhanji R, Abdullah T, Vachon-Presseau E, Berger S et al. Sex-Specific Pharmacotherapy for Back Pain: A Proof-of-Concept Randomized Trial. Pain Ther 2021 Dec;10(2):1375-1400. doi:10.1007/s40122-021-00297-2
- Edwards WB, Haider IT, Simonian N, Barroso J, Schnitzer TJ Durability and delayed treatment effects of zoledronic acid on bone loss after spinal cord injury: a randomized, controlled trial. J Bone Miner Res 2021 Nov;36(11):2127-2138. doi:10.1002/jbmr.4416
- Hochberg MC, Carrino JA, Schnitzer TJ, Guermazi A, Walsh DA, White A, Nakajo S, Fountaine RJ, Hickman A, Pixton G et al. Long-Term Safety and Efficacy of Subcutaneous Tanezumab Versus Nonsteroidal Antiinflammatory Drugs for Hip or Knee Osteoarthritis: A Randomized Trial. Arthritis Rheumatol 2021 Jul;73(7):1167-1177. doi:10.1002/art.41674
- Wakaizumi K, Vigotsky AD, Jabakhanji R, Abdallah M, Barroso J, Schnitzer TJ, Apkarian AV, Baliki MN Psychosocial, Functional, and Emotional Correlates of Long-Term Opioid Use in Patients with Chronic Back Pain: A Cross-Sectional Case-Control Study. Pain Ther 2021 Jun;10(1):691-709. doi:10.1007/s40122-021-00257-w
- Troy KL, Mancuso ME, Johnson JE, Butler TA, Ngo BH, Schnitzer TJ Dominant and nondominant distal radius microstructure: Predictors of asymmetry and effects of a unilateral mechanical loading intervention. Bone Rep 2021 Jun;14:101012. pii:101012
- Reckziegel D, Abdullah T, Wu B, Wu B, Huang L, Schnitzer TJ, Apkarian AV Hippocampus shape deformation: a potential diagnostic biomarker for chronic back pain in women. Pain 2021 May 01;162(5):1457-1467. doi:10.1097/j.pain.0000000000002143
- Barroso J, Wakaizumi K, Reis AM, Baliki M, Schnitzer TJ, Galhardo V, Apkarian AV Reorganization of functional brain network architecture in chronic osteoarthritis pain. Hum Brain Mapp 2021 Mar;42(4):1206-1222. doi:10.1002/hbm.25287
- Haider IT, Simonian N, Schnitzer TJ, Edwards WB Stiffness and Strength Predictions From Finite Element Models of the Knee are Associated with Lower-Limb Fractures After Spinal Cord Injury. Ann Biomed Eng 2021 Feb;49(2):769-779. doi:10.1007/s10439-020-02606-w
- Barroso J, Vigotsky AD, Branco P, Reis AM, Schnitzer TJ, Galhardo V, Apkarian AV Brain gray matter abnormalities in osteoarthritis pain: a cross-sectional evaluation. Pain 2020 Sep 01;161(9):2167-2178. doi:10.1097/j.pain.0000000000001904
- Troy KL, Mancuso ME, Johnson JE, Wu Z, Schnitzer TJ, Butler TA Bone Adaptation in Adult Women Is Related to Loading Dose: A 12-Month Randomized Controlled Trial. J Bone Miner Res 2020 Jul;35(7):1300-1312. doi:10.1002/jbmr.3999
- Schnitzer TJ, Khan A, Bessette L, Davignon I, Brown MT, Pixton G, Prucka WR, Tive L, Viktrup L, West CR Onset and maintenance of efficacy of subcutaneous tanezumab in patients with moderate to severe osteoarthritis of the knee or hip: A 16-week dose-titration study. Semin Arthritis Rheum 2020 Jun;50(3):387-393. doi:10.1016/j.semarthrit.2020.03.004
- Smith BC, Vigotsky AD, Apkarian AV, Schnitzer TJ Temporal Factors Associated With Opioid Prescriptions for Patients With Pain Conditions in an Urban Emergency Department. JAMA Netw Open 2020 Mar 02;3(3):e200802. pii:e200802
- Dakin P, DiMartino SJ, Gao H, Maloney J, Kivitz AJ, Schnitzer TJ, Stahl N, Yancopoulos GD, Geba GP The Efficacy, Tolerability, and Joint Safety of Fasinumab in Osteoarthritis Pain: A Phase IIb/III Double-Blind, Placebo-Controlled, Randomized Clinical Trial. Arthritis Rheumatol 2019 Nov;71(11):1824-1834. doi:10.1002/art.41012
- Haider IT, Simonian N, Saini AS, Leung FM, Edwards WB, Schnitzer TJ Open-label clinical trial of alendronate after teriparatide therapy in people with spinal cord injury and low bone mineral density. Spinal Cord 2019 Oct;57(10):832-842. doi:10.1038/s41393-019-0303-3
- Vachon-Presseau E, Berger SE, Abdullah TB, Griffith JW, Schnitzer TJ, Apkarian AV Identification of traits and functional connectivity-based neurotraits of chronic pain. PLoS Biol 2019 Aug;17(8):e3000349. pii:e3000349
- Smith TO, Mansfield M, Hawker GA, Hunter DJ, March LM, Boers M, Shea BJ, Christensen R, Guillemin F, Terwee CB et al. Uptake of the OMERACT-OARSI Hip and Knee Osteoarthritis Core Outcome Set: Review of Randomized Controlled Trials from 1997 to 2017. J Rheumatol 2019 Aug;46(8):976-980. doi:10.3899/jrheum.181066
- Smith TO, Hawker GA, Hunter DJ, March LM, Boers M, Shea BJ, Christensen R, Guillemin F, Terwee CB, Williamson PR et al. The OMERACT-OARSI Core Domain Set for Measurement in Clinical Trials of Hip and/or Knee Osteoarthritis. J Rheumatol 2019 Aug;46(8):981-989. doi:10.3899/jrheum.181194
- Schnitzer TJ, Easton R, Pang S, Levinson DJ, Pixton G, Viktrup L, Davignon I, Brown MT, West CR, Verburg KM Effect of Tanezumab on Joint Pain, Physical Function, and Patient Global Assessment of Osteoarthritis Among Patients With Osteoarthritis of the Hip or Knee: A Randomized Clinical Trial. JAMA 2019 Jul 02;322(1):37-48. doi:10.1001/jama.2019.8044
- Fleischmann RM, Bliddal H, Blanco FJ, Schnitzer TJ, Peterfy C, Chen S, Wang L, Feng S, Conaghan PG, Berenbaum F et al. A Phase II Trial of Lutikizumab, an Anti-Interleukin-1α/β Dual Variable Domain Immunoglobulin, in Knee Osteoarthritis Patients With Synovitis. Arthritis Rheumatol 2019 Jul;71(7):1056-1069. doi:10.1002/art.40840
- Reckziegel D, Vachon-Presseau E, Petre B, Schnitzer TJ, Baliki MN, Apkarian AV Deconstructing biomarkers for chronic pain: context- and hypothesis-dependent biomarker types in relation to chronic pain. Pain 2019 May;160 Suppl 1(Suppl 1):S37-S48. doi:10.1097/j.pain.0000000000001529
- Tive L, Bello AE, Radin D, Schnitzer TJ, Nguyen H, Brown MT, West CR Pooled analysis of tanezumab efficacy and safety with subgroup analyses of phase III clinical trials in patients with osteoarthritis pain of the knee or hip. J Pain Res 2019;12:975-995. doi:10.2147/JPR.S191297